| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Fmoc-Lys(Fmoc)-OH does not have a specific biological target. Its primary utility is as a chemical building block in organic synthesis, particularly in Fmoc-based peptide synthesis. The compound serves as a protected lysine unit that can be incorporated into peptide chains while the Fmoc groups protect both amino groups from unwanted reactions. Lysine is an essential amino acid involved in protein synthesis and post-translational modifications, but in its protected form, the compound is not designed to interact with biological receptors or enzymes. Its value lies in its chemical properties as a synthetic intermediate, enabling the construction of complex peptides and pharmaceutical compounds.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
Fmoc-Lys(Fmoc)-OH does not exhibit pharmacological activity in vitro. As a protected amino acid derivative, it is a synthetic intermediate rather than a bioactive compound. In vitro studies using this compound focus on its chemical reactivity, such as its use in peptide bond formation reactions and selective deprotection strategies, rather than assessments of pharmacological activity. The compound may be used as a substrate in enzymatic assays to study the cleavage of Fmoc protecting groups, but these are analytical applications rather than pharmacological assessments. The compound does not bind to receptors, inhibit enzymes, or produce cytotoxic effects in cell-based assays at concentrations typically used for synthesis. Its role in research is almost exclusively as a reagent for organic synthesis. |
| ln Vivo |
Fmoc-Lys(Fmoc)-OH is not a pharmacologically active compound and therefore does not have defined in vivo activity as a drug. When administered to animals, the compound would likely be metabolized to release lysine, which would then enter normal metabolic pathways. However, the compound is not used therapeutically, and its in vivo effects would be limited to those of the released lysine. Its primary value remains in synthetic chemistry, where it serves as a building block for the preparation of peptides and pharmaceutical compounds.
|
| Enzyme Assay |
In vitro assays for Fmoc-Lys(Fmoc)-OH are primarily focused on its chemical properties and reactivity rather than biological activity. Standard protocols in Fmoc-based solid-phase peptide synthesis involve the use of this compound as a doubly protected lysine building block. The compound is typically dissolved in polar aprotic solvents such as DMF or DCM and coupled to a growing peptide chain on a solid support using standard peptide coupling reagents such as HATU, HOBt, or DIC. The progress of the coupling reaction can be monitored by HPLC or TLC. The Fmoc groups can be removed under basic conditions (e.g., 20% piperidine in DMF), revealing the free amino groups for further functionalization or peptide chain elongation.
|
| Cell Assay |
In vitro cellular assays using Fmoc-Lys(Fmoc)-OH are not commonly performed because the compound lacks intrinsic biological activity. The compound is used exclusively in synthetic chemistry applications and is not designed for cell culture studies. Its use is confined to the laboratory, where it serves as a building block for the preparation of peptides and pharmaceutical compounds.
|
| Animal Protocol |
In vivo animal studies with Fmoc-Lys(Fmoc)-OH are not typically conducted, as the compound is a synthetic intermediate rather than a pharmacologically active agent. If used in vivo, the compound would be administered to animals to study the metabolism of protected amino acid derivatives. However, such studies are rare, and the compound is generally used exclusively in synthetic chemistry applications. Its use is confined to the laboratory, where it serves as a building block for the preparation of peptides and pharmaceutical compounds.
|
| ADME/Pharmacokinetics |
Fmoc-Lys(Fmoc)-OH is not a drug candidate, and pharmacokinetic data are not available. As a protected amino acid derivative, it is designed for chemical synthesis rather than systemic administration. If administered in vivo, the compound would likely be metabolized to release lysine. The compound's pharmacokinetic properties have not been characterized, and its use is confined to in vitro synthetic applications.
|
| Toxicity/Toxicokinetics |
The compound is generally considered to have low toxicity, consistent with its use as a chemical reagent. The compound should be stored at -20°C for long-term stability. Standard laboratory safety precautions, including the use of personal protective equipment, are recommended. It is not classified as a highly toxic substance, but appropriate safety measures should be followed. Inhalation, ingestion, or skin contact should be avoided.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1144.
|
| Additional Infomation |
Fmoc-Lys(Fmoc)-OH (Nα,Nε-bis-[(9H-Fluoren-9-ylmethoxy)carbonyl]-L-lysine, CAS 78081-87-5) is a protected amino acid derivative used as a building block in peptide synthesis. Its chemical formula is C₄₁H₃₆N₂O₆ and molecular weight is approximately 652.73 g/mol. The compound features Fmoc groups protecting both the α-amino and ε-amino groups. It is intended for research use only and is not for human therapeutic applications. The compound is typically stored at -20°C for long-term stability.
|
| Molecular Formula |
C36H34N2O6
|
|---|---|
| Molecular Weight |
590.6650
|
| Exact Mass |
590.241
|
| CAS # |
78081-87-5
|
| PubChem CID |
13783708
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
835.2±65.0 °C at 760 mmHg
|
| Melting Point |
120-130°C
|
| Flash Point |
458.9±34.3 °C
|
| Vapour Pressure |
0.0±3.2 mmHg at 25°C
|
| Index of Refraction |
1.630
|
| LogP |
7.41
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
44
|
| Complexity |
946
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O(C(N([H])[C@]([H])(C(=O)O[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=O)OC([H])([H])C1([H])C2=C([H])C([H])=C([H])C([H])=C2C2=C([H])C([H])=C([H])C([H])=C12)=O)C([H])([H])C1([H])C2=C([H])C([H])=C([H])C([H])=C2C2=C([H])C([H])=C([H])C([H])=C12
|
| InChi Key |
BMJRTKDVFXYEFS-XIFFEERXSA-N
|
| InChi Code |
InChI=1S/C36H34N2O6/c39-34(40)33(38-36(42)44-22-32-29-17-7-3-13-25(29)26-14-4-8-18-30(26)32)19-9-10-20-37-35(41)43-21-31-27-15-5-1-11-23(27)24-12-2-6-16-28(24)31/h1-8,11-18,31-33H,9-10,19-22H2,(H,37,41)(H,38,42)(H,39,40)/t33-/m0/s1
|
| Chemical Name |
(2S)-2,6-bis(9H-fluoren-9-ylmethoxycarbonylamino)hexanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMF : 100 mg/mL (~169.30 mM)
DMSO : ~100 mg/mL (~169.30 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.23 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.23 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.23 mM) (saturation unknown) in 10% DMF 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6930 mL | 8.4650 mL | 16.9299 mL | |
| 5 mM | 0.3386 mL | 1.6930 mL | 3.3860 mL | |
| 10 mM | 0.1693 mL | 0.8465 mL | 1.6930 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
